Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

ARS Pharmaceuticals (SPRY) Accumulated Depreciation & Amortization (2021 - 2024)

ARS Pharmaceuticals' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $100000.0 for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization changed 0.0% year-over-year to $100000.0; the TTM value through Dec 2024 reached $100000.0, changed 0.0%, while the annual FY2024 figure was $100000.0, 0.0% changed from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $100000.0 at ARS Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $100000.0 in Q4 2022 and bottomed at $14000.0 in Q4 2021.
  • The 4-year median for Accumulated Depreciation & Amortization is $100000.0 (2022), against an average of $85666.7.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 614.29% in 2022 before it changed 0.0% in 2023.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $14000.0 in 2021, then soared by 614.29% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024.
  • Per Business Quant, the three most recent readings for SPRY's Accumulated Depreciation & Amortization are $100000.0 (Q4 2024), $100000.0 (Q3 2024), and $100000.0 (Q4 2023).